Michael R Harrison

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor
    Michael R Harrison
    Section of Hematology Oncology, Department of Medicine, University of Wisconsin, UW Carbone Cancer Center, Madison, Wisconsin, USA
    Oncology (Williston Park) 23:792-5. 2009
  2. pmc Pazopanib for the treatment of patients with advanced renal cell carcinoma
    Joshua M Lang
    Carbone Cancer Center, University of Wisconsin, 7020 Wisconsin Institutes for Medical Research, Madison, WI 53705 2225, USA
    Clin Med Insights Oncol 4:95-105. 2010
  3. pmc A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
    Michael R Harrison
    University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA
    Invest New Drugs 29:1465-74. 2011
  4. doi request reprint Better late than early: FDG-PET imaging in metastatic renal cell carcinoma
    Michael R Harrison
    Divisions of Medical Oncology, Department of Medicine, and Urology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 17:5841-3. 2011

Detail Information

Publications4

  1. ncbi request reprint Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor
    Michael R Harrison
    Section of Hematology Oncology, Department of Medicine, University of Wisconsin, UW Carbone Cancer Center, Madison, Wisconsin, USA
    Oncology (Williston Park) 23:792-5. 2009
    ..We report the case of an advanced granulosa cell tumor of the testis with a confirmed partial response to an angiogenesis inhibitor after initial resistance to cytotoxic chemotherapy...
  2. pmc Pazopanib for the treatment of patients with advanced renal cell carcinoma
    Joshua M Lang
    Carbone Cancer Center, University of Wisconsin, 7020 Wisconsin Institutes for Medical Research, Madison, WI 53705 2225, USA
    Clin Med Insights Oncol 4:95-105. 2010
    ..Finally, an algorithm utilizing Level I evidence for the treatment of patients with this disease will be proposed...
  3. pmc A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
    Michael R Harrison
    University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA
    Invest New Drugs 29:1465-74. 2011
    ..Preclinical data support antitumor activity in prostate cancer. This trial evaluated the efficacy of 2ME2 NCD in patients with taxane-refractory, metastatic CRPC...
  4. doi request reprint Better late than early: FDG-PET imaging in metastatic renal cell carcinoma
    Michael R Harrison
    Divisions of Medical Oncology, Department of Medicine, and Urology, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 17:5841-3. 2011
    ..Further work is needed to personalize treatment for patients with mRCC...